Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
Abstract We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvo...
Uloženo v:
| Vydáno v: | Open forum infectious diseases Ročník 8; číslo 2; s. ofab050 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
US
Oxford University Press
01.02.2021
|
| Témata: | |
| ISSN: | 2328-8957, 2328-8957 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
We report a real-world experience using fluvoxamine for early COVID-19. Incidence of hospitalization was 0% (0/65) with fluvoxamine and 12.5% (6/48) with observation alone. At 14 days, residual symptoms persisted in 0% (0/65) with fluvoxamine and 60% (29/48) with observation. |
|---|---|
| AbstractList | We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation. We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation. We report a real-world experience using fluvoxamine for early COVID-19. Incidence of hospitalization was 0% (0/65) with fluvoxamine and 12.5% (6/48) with observation alone. At 14 days, residual symptoms persisted in 0% (0/65) with fluvoxamine and 60% (29/48) with observation. Abstract We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation. We report a real-world experience using fluvoxamine for early COVID-19. Incidence of hospitalization was 0% (0/65) with fluvoxamine and 12.5% (6/48) with observation alone. At 14 days, residual symptoms persisted in 0% (0/65) with fluvoxamine and 60% (29/48) with observation. We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation. |
| Author | Seftel, David Boulware, David R |
| AuthorAffiliation | 1 Golden Gate Fields Medical Clinic , Berkeley, California, USA 3 University of Minnesota Medical School , Minneapolis, Minnesota, USA 2 Enable Biosciences Inc , South San Francisco, California, USA |
| AuthorAffiliation_xml | – name: 1 Golden Gate Fields Medical Clinic , Berkeley, California, USA – name: 3 University of Minnesota Medical School , Minneapolis, Minnesota, USA – name: 2 Enable Biosciences Inc , South San Francisco, California, USA |
| Author_xml | – sequence: 1 givenname: David surname: Seftel fullname: Seftel, David email: dseftel@enablebiosciences.com organization: Golden Gate Fields Medical Clinic, Berkeley, California, USA – sequence: 2 givenname: David R orcidid: 0000-0002-4715-0060 surname: Boulware fullname: Boulware, David R email: dseftel@enablebiosciences.com organization: University of Minnesota Medical School, Minneapolis, Minnesota, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33623808$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc1P3DAQxa0KVD7KrecqEodyYKk_kti-VKoWKEhIcKBny3HGxSjJLHayKv89XnapKFK5jEfyb57ezNsjWwMOQMhnRk8Y1eIb-tDmYhta0Q9klwuuZkpXcutVv0MOUrqnlDKWKak_kh0hai4UVbvk-iZiWoAbwxKKOd5hHAv0xXk3LfGP7cMAhcdYnNnYPRa3EezYw_CMzDHiYJchTqk4DQlsgoLpT2Tb2y7BwebdJ7_Oz27nF7Or65-X8x9XM1dJOc4kyEY5pipPpdUttw33jIOuXMlrJSxvqa2g9LxmZQMaGANfe-pK39JWKy72yfe17mJqemhdNhVtZxYx9DY-GrTB_PszhDvzG5dGKqWquswCRxuBiA8TpNH0ITnoOjsATsnwUgtKBZcso4dv0Huc4pDXM4JJxiTVFc3Ul9eO_lp5uXUG-Bpw-eQpgjcujHYMuDIYOsOoWWVqVpmaTaZ56PjN0Ivuf_CvaxynxfvkE2Y2spA |
| CitedBy_id | crossref_primary_10_1177_20587384211048026 crossref_primary_10_1002_cbf_3789 crossref_primary_10_1371_journal_pone_0310438 crossref_primary_10_1186_s12916_023_02877_9 crossref_primary_10_1192_bjo_2021_1053 crossref_primary_10_1038_s41380_023_02004_3 crossref_primary_10_1097_JCP_0000000000001721 crossref_primary_10_1159_000522115 crossref_primary_10_3390_ijms242317039 crossref_primary_10_3390_v16040545 crossref_primary_10_1038_s41380_021_01432_3 crossref_primary_10_1038_s41577_022_00734_z crossref_primary_10_1097_IPC_0000000000001371 crossref_primary_10_1016_j_biopha_2024_117783 crossref_primary_10_1016_j_cmi_2023_01_010 crossref_primary_10_3390_jcm11144038 crossref_primary_10_3390_ph14070691 crossref_primary_10_7717_peerj_12595 crossref_primary_10_1016_j_jiph_2023_10_010 crossref_primary_10_1038_s41380_021_01309_5 crossref_primary_10_3389_fphar_2021_787261 crossref_primary_10_1177_10600280211028242 crossref_primary_10_3390_jcm10245891 crossref_primary_10_3390_bioengineering10050514 crossref_primary_10_1080_07853890_2022_2034936 crossref_primary_10_1038_s41398_022_02109_3 crossref_primary_10_1080_14728222_2021_1952987 crossref_primary_10_1016_j_ijid_2023_06_018 crossref_primary_10_3390_ijms24031997 crossref_primary_10_12688_f1000research_53275_2 crossref_primary_10_1192_bjo_2021_1075 crossref_primary_10_3389_fpsyt_2022_951065 crossref_primary_10_12688_f1000research_53275_3 crossref_primary_10_1038_s41398_023_02343_3 crossref_primary_10_1097_MJT_0000000000001502 crossref_primary_10_3390_jpm12091487 crossref_primary_10_3390_ijms23073812 crossref_primary_10_1016_j_euroneuro_2023_03_011 crossref_primary_10_7759_cureus_34158 crossref_primary_10_1007_s00216_023_04825_1 crossref_primary_10_1111_bcp_15126 crossref_primary_10_1016_j_jiph_2022_10_010 crossref_primary_10_1001_jamanetworkopen_2022_6269 crossref_primary_10_1016_j_cmi_2022_08_013 crossref_primary_10_1016_j_jinf_2022_10_012 crossref_primary_10_3389_fphar_2022_1036093 crossref_primary_10_1186_s40246_023_00521_4 crossref_primary_10_1002_cpt_2317 crossref_primary_10_1001_jamanetworkopen_2021_36510 crossref_primary_10_3389_fpsyt_2022_1052710 crossref_primary_10_1055_a_2177_3056 crossref_primary_10_1097_NUR_0000000000000696 crossref_primary_10_3389_fpsyt_2025_1340179 crossref_primary_10_1007_s00228_022_03372_5 crossref_primary_10_1016_j_rcsop_2023_100232 crossref_primary_10_1038_s41398_024_03185_3 crossref_primary_10_3390_v14112417 crossref_primary_10_1001_jama_2022_24100 crossref_primary_10_1001_jamanetworkopen_2021_33090 crossref_primary_10_1016_j_aprim_2023_102771 crossref_primary_10_1371_journal_pone_0271574 crossref_primary_10_1038_s41598_024_64260_9 crossref_primary_10_1007_s40263_022_00931_3 crossref_primary_10_3389_fphar_2022_1054644 crossref_primary_10_3389_fpsyt_2021_798554 crossref_primary_10_1016_j_ijpharm_2021_121023 crossref_primary_10_1038_s41380_021_01254_3 crossref_primary_10_1093_jphsr_rmad031 crossref_primary_10_3389_fphar_2022_849095 crossref_primary_10_1007_s11055_023_01369_w crossref_primary_10_1056_NEJMoa2201662 crossref_primary_10_3390_molecules26123526 crossref_primary_10_1007_s44192_023_00036_3 crossref_primary_10_3390_ph16081107 crossref_primary_10_1007_s00228_023_03517_0 crossref_primary_10_3201_eid2711_211449 crossref_primary_10_3390_jcm11010070 crossref_primary_10_1128_mSystems_00233_21 crossref_primary_10_1038_s41398_022_01804_5 crossref_primary_10_1016_j_bpsgos_2021_12_007 crossref_primary_10_1016_j_jsps_2022_05_004 crossref_primary_10_3389_fphar_2021_652688 crossref_primary_10_1007_s40265_022_01682_7 crossref_primary_10_1016_j_cmi_2023_04_028 crossref_primary_10_1007_s00406_021_01326_z crossref_primary_10_2147_DDDT_S392708 crossref_primary_10_1016_j_eclinm_2024_102517 crossref_primary_10_1016_j_euroneuro_2023_06_005 crossref_primary_10_1016_j_cct_2022_106755 crossref_primary_10_3390_ijms232113623 crossref_primary_10_1016_j_ccm_2022_11_008 crossref_primary_10_1038_s41380_021_01393_7 crossref_primary_10_1080_14656566_2022_2035360 crossref_primary_10_1002_hsr2_892 crossref_primary_10_1055_a_1717_2381 crossref_primary_10_1097_MJT_0000000000001496 crossref_primary_10_3390_pathogens11020275 crossref_primary_10_1007_s40265_021_01636_5 crossref_primary_10_3390_jcm11195882 |
| Cites_doi | 10.1001/jama.2020.22760 10.1126/scitranslmed.aau5266 10.1161/CIRCULATIONAHA.120.051718 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2021 The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2021 – notice: The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. – notice: The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | TOX AAYXX CITATION NPM 3V. 7X7 7XB 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1093/ofid/ofab050 |
| DatabaseName | Oxford Journals Open Access Collection CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Public Health ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2328-8957 |
| ExternalDocumentID | PMC7888564 33623808 10_1093_ofid_ofab050 10.1093/ofid/ofab050 |
| Genre | Journal Article Report |
| GroupedDBID | 0R~ 53G 5VS AAFWJ AAMVS AAPPN AAPXW AAVAP ABDBF ABEJV ABGNP ABPTD ABXVV ACGFS ACUHS ADBBV ADHZD ADPDF ADRAZ AENZO AFPKN AFULF ALMA_UNASSIGNED_HOLDINGS ALUQC AMNDL AOIJS BAWUL BAYMD BCNDV BTTYL CIDKT DIK EBS EJD GROUPED_DOAJ H13 HYE IAO IHR ITC KQ8 KSI M48 M~E O9- OAWHX OJQWA OK1 OVD OVEED PEELM ROL ROX RPM TEORI TJX TOX 7X7 8C1 8FI 8FJ AAYXX ABUWG AFFHD AFKRA BENPR CCPQU CITATION FYUFA HMCUK PHGZM PHGZT PIMPY PJZUB PPXIY UKHRP NPM 3V. 7XB 8FK AZQEC COVID DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c577t-7e7b8c185f07a9d2ab2f12e95c42683a2d0a5e4f2614be9e11ef6f0c4fd0d9823 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 105 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000637323400073&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2328-8957 |
| IngestDate | Tue Nov 04 01:57:22 EST 2025 Thu Oct 02 06:31:31 EDT 2025 Tue Oct 07 07:38:55 EDT 2025 Mon Jul 21 06:05:53 EDT 2025 Tue Nov 18 22:39:50 EST 2025 Sat Nov 29 01:54:39 EST 2025 Thu Jan 30 13:18:23 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | COVID-19 cohort coronavirus fluvoxamine SARS-COV-2 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com http://creativecommons.org/licenses/by-nc-nd/4.0 The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c577t-7e7b8c185f07a9d2ab2f12e95c42683a2d0a5e4f2614be9e11ef6f0c4fd0d9823 |
| Notes | SourceType-Scholarly Journals-1 content type line 14 ObjectType-Report-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-4715-0060 |
| OpenAccessLink | https://www.proquest.com/docview/3171170950?pq-origsite=%requestingapplication% |
| PMID | 33623808 |
| PQID | 3171170950 |
| PQPubID | 7089189 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7888564 proquest_miscellaneous_2493003271 proquest_journals_3171170950 pubmed_primary_33623808 crossref_citationtrail_10_1093_ofid_ofab050 crossref_primary_10_1093_ofid_ofab050 oup_primary_10_1093_ofid_ofab050 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-01 2021-Feb 20210201 |
| PublicationDateYYYYMMDD | 2021-02-01 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: United States – name: Oxford |
| PublicationTitle | Open forum infectious diseases |
| PublicationTitleAlternate | Open Forum Infect Dis |
| PublicationYear | 2021 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Rosen (2021021717275727400_CIT0002) 2019; 11 Franklin (2021021717275727400_CIT0003) 2020 Lenze (2021021717275727400_CIT0001) 2020; 324 |
| References_xml | – volume: 324 start-page: 2292 year: 2020 ident: 2021021717275727400_CIT0001 article-title: Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic covid-19: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2020.22760 – volume: 11 start-page: eaau5266 year: 2019 ident: 2021021717275727400_CIT0002 article-title: Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aau5266 – year: 2020 ident: 2021021717275727400_CIT0003 article-title: Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.051718 |
| SSID | ssj0001105079 |
| Score | 2.5271888 |
| SecondaryResourceType | review_article |
| Snippet | Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak.... We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall,... |
| SourceID | pubmedcentral proquest pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | ofab050 |
| SubjectTerms | Brief Report Editor's Choice |
| Title | Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33623808 https://www.proquest.com/docview/3171170950 https://www.proquest.com/docview/2493003271 https://pubmed.ncbi.nlm.nih.gov/PMC7888564 |
| Volume | 8 |
| WOSCitedRecordID | wos000637323400073&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVASL databaseName: Oxford Journals Open Access Collection customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: TOX dateStart: 20140101 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2328-8957 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 7X7 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2328-8957 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: BENPR dateStart: 20140401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 2328-8957 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 8C1 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2328-8957 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: PIMPY dateStart: 20140401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwED6xbpp4ATY2CIzKSPCEojm_avsJQVkF0tZFqJvKU2Q7jlZpJKNpK_58zonTtUjAAy-WLJ8UK2f7Pt-dvwN4Y7QquJDSz5PY-JYL01eM4mEotGSRQsDblHu7PmfjMZ9OReocbrVLq-zOxOagzittfeSnaOdskRSR0Pd3P3xbNcpGV10JjR3YtUxlcQ92P56N06_3XhaED5QJl_GOt_dTVFmOjVTUPrXfsEVb79s2YObv2ZIb5mf0-H8n_gQeOeBJPrQr5QAemPIQ9i9caP0pXKbzqnt2SYbVDcJyUhVkdLtcVT_ld5QhiG9JQ4hMJl16uhUZWhIEuZrNlzX51MZ7SCCO4Gp0Nhl-9l21BV8njC18ZpjiGs13QZkUeShVWAShEYlGI84jGeZUJiYu8MoVKyNMEJhiUFAdFznNBar0GHplVZrnQAYySlhgEp5bgBZIYThFWBHHKtKIOZQH77r_nmlHRW4rYtxmbUg8yqyWMqclD96upe9aCo4_yBFU4T9ETjodZW6v1tm9gjx4vR7GXWZDJ7I01bLO8JIa4fkXssCDZ-1yWH8oQgwQcco9YFsLZS1gGby3R8rZTcPkbf0PySB-8fdpvYSHoc2kaXLFT6C3mC_NK9jTq8Wsnvdhh01Z03Js-TDou03Qb_wL2Eu_XKTfsDe5nP4CrzsUzQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB5VKQIuvB-GAotET8jq2mtndw8IoZSoUZOQQ0Dl5O6u12qkYpc4CfCn-I3M-pEmSMCpBy6-eCQ_9tuZb3ZeAK-s0ZmQSvlpHFnf9cL0NaeoDKVRnGkkvNW4t09DPh6LkxM52YGfbS2MS6tsdWKlqNPCuDPyA7RzbkiKjOnbi6--mxrloqvtCI0aFsf2xzd02co3g0Nc3_0w7L-f9o78ZqqAb2LOFz63XAuDZiqjXMk0VDrMgtDK2KCxEkyFKVWxjTJ0LSJtpQ0Cm3UzaqIspakUrtEBqvzdCMEuOrA7GYwmny9PdZCuUC6bDHsq2QFCJMWL0tSV9m_Yvq16ug1a-3t25oa569_-337UHbjVEGvyrt4Jd2HH5vfg-qhJHbgPHybzoi0rJb3iDN0OUmSkf75cFd_VF5QhyN9J1fCZTNv0eyfSc00e1Go2X5bksI5nkUA-gI9X8jkPoZMXuX0MpKtYzAMbi9QR0EBJKyjSpijSzCCn0h68btc5MU2rdTfx4zypQ_4scahIGlR4sL-WvqhbjPxBjiBk_iGy12IiaXRRmVwCwoOX69uoRVxoSOW2WJYJOuEM9XvIAw8e1fBbP4ghx2GCCg_4FjDXAq5D-fadfHZWdSp35ytxN3ry99d6ATeOpqNhMhyMj5_CzdBlDVV58XvQWcyX9hlcM6vFrJw_b7YbgdOrBu4vKlpscg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prospective+Cohort+of+Fluvoxamine+for+Early+Treatment+of+Coronavirus+Disease+19&rft.jtitle=Open+forum+infectious+diseases&rft.au=Seftel%2C+David&rft.au=Boulware%2C+David+R&rft.date=2021-02-01&rft.pub=Oxford+University+Press&rft.eissn=2328-8957&rft.volume=8&rft.issue=2&rft_id=info:doi/10.1093%2Fofid%2Fofab050&rft_id=info%3Apmid%2F33623808&rft.externalDocID=PMC7888564 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon |